Wockhardt says it is NOT selling assets in the US to Mylan and or Roche in order to concentrate on international business opportunties. Reports are circulating that Wockhardt because of fiarl recent FDA bans on import of its product to the US from two failed manufacturing plants has decided to cash this assets in.
Mylan is most often mentioned as the buyer of its domestic (India) business for upwards of $1 B according to these sources. Wockhardt stock surged on the news so while its management may be denying the rumors, its shareholders are looking forward to a sale. See Bloomberg.
Posted by Bruce Lehr April 29th 2014.